SCHEDULE 13G/A: Armistice Capital and Steven Boyd Disclose 7.68% Stake in PROMIS NEUROSCIENCES INC.

Armistice Capital, LLC and its managing member Steven Boyd have disclosed a beneficial ownership of 7.68% in PROMIS NEUROSCIENCES INC., totaling 2,509,977 common shares.

Summary

• Armistice Capital, LLC and Steven Boyd, collectively referred to as the 'Reporting Persons', have filed an Amendment No. 1 to Schedule 13G.
• The filing discloses their beneficial ownership in PROMIS NEUROSCIENCES INC. (Issuer) as of December 31, 2024.
• The Reporting Persons collectively beneficially own 2,509,977 common shares of PROMIS NEUROSCIENCES INC.
• This ownership represents 7.68% of the Issuer's outstanding common shares.
• The percentage is calculated based on 32,689,190 shares outstanding as of November 14, 2024, as reported in the Issuer's Form 10-Q.
• Armistice Capital, LLC, a Delaware entity, acts as the investment manager for Armistice Capital Master Fund Ltd., which is the direct holder of the shares.
• Steven Boyd, a U.S. citizen, is the managing member of Armistice Capital, LLC.
• Both Armistice Capital, LLC and Steven Boyd share voting and dispositive power over the 2,509,977 shares.
• The shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the Issuer.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that inherently conveys positive or negative sentiment regarding the company's performance or outlook. It is a neutral regulatory filing.

Future Outlook

NA

Industry Context

This filing is a standard disclosure of a significant ownership stake by an institutional investor in a publicly traded company. It reflects an investment decision by Armistice Capital, LLC and Steven Boyd in PROMIS NEUROSCIENCES INC., a company in the biotechnology or pharmaceutical sector, given its name. Such disclosures are common and provide transparency regarding major shareholders.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's stake, which can influence market perception and potentially signal confidence or interest in the company.

Key Dates

Keywords

PROMIS NEUROSCIENCES INC., Armistice Capital, Steven Boyd, Schedule 13G, Beneficial Ownership, Common Shares, Investment Management, SEC Filing, Institutional Investor